Multiple studies highlight fidaxomicin’s effectiveness across high-risk populations despite cost and access challenges, underscoring the need for education and stewardship to improve guideline adherence.
At MAD-ID 2025, a clear theme emerged showing fidaxomicin as the preferred treatment for Clostridioides difficile infection (CDI) in patients at risk of recurrence. Studies demonstrated fidaxomicin reduces recurrence rates compared to vancomycin in groups including older adults, immunocompromised patients, transplant recipients, and those undergoing chemotherapy. Although the initial cost of fidaxomicin is higher, its use can lead to fewer readmissions and lower overall healthcare costs. Barriers such as cost and formulary restrictions continue to limit its use, highlighting the need for provider education and patient assistance programs to support wider adoption in line with current guidelines.
